SEC Filing Summary: Nuvilex, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (not Pharmacyte Biotech, Inc.) on November 3, 2009, reporting an event that occurred on October 23, 2009. The registrant is incorporated in Nevada and maintains its principal executive offices in Cherry Hill, New Jersey.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Robert J. Creeden resigned from the Board of Directors on October 23, 2009.
- Reason: The resignation was necessitated by policies from Partners Innovation Fund and its parent, Partners Healthcare, regarding the holding of board seats for publicly traded companies.
- Background: Mr. Creeden previously served on the board of Freedom2 and joined Nuvilex to provide continuity during a transition period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the specific governance change noted above.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Creeden's departure.
- Confirm whether a replacement director has been appointed to maintain board quorum and continuity.
- Review the relationship between Nuvilex, Inc. and Freedom2 to understand the context of the "transition period" mentioned.
- Note the discrepancy between the requested company name (Pharmacyte Biotech, Inc.) and the actual registrant (Nuvilex, Inc.).